Skip to content
Review Open access

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology

Sep 2026 · Frontiers in Cardiovascular Medicine · Vol 13 · 0 citations · 83 references
Medicine

TL;DR

This Review provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium–glucose cotransporter 2 inhibitor use and patient-specific treatment constraints.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have expanded from glucose-lowering therapy into cardiovascular medicine. In type 2 diabetes, several long-acting GLP-1RAs reduce major adverse cardiovascular events (MACE). SELECT extended this benefit to adults with established cardiovascular disease and overweight or obesity without diabetes, while SOUL demonstrated MACE reduction with oral semaglutide. SURPASS-CVOT established cardiovascular noninferiority of tirzepatide to dulaglutide but did not demonstrate superiority. Obesity-related heart failure with preserved ejection fraction (HFpEF) has emerged as a particularly responsive phenotype: semaglutide improves symptoms and physical function, whereas tirzepatide also reduces worsening heart failure events. FLOW further supports kidney and cardiovascular protection with semaglutide in type 2 diabetes and chronic kidney disease. Randomised human studies support effects on adiposity, haemodynamic burden, inflammation and cardiorenal outcomes, whereas endothelial, coronary microvascular and direct myocardial mechanisms remain less clinically validated. This Review integrates the current evidence, distinguishes randomised outcomes from observational and mechanistic signals, and provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium–glucose cotransporter 2 inhibitor use and patient-specific treatment constraints. Current practice should be guided by indication-specific outcome evidence rather than weight-loss magnitude or indirect cross-trial comparisons.

Read PDF

Similar papers

Review Open access Oct 2026

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence diff...

Filip Kierzkowski, Wiktoria Skrzypek, W. Bryl et al. · 0 citations
Review Open access Aug 2026

Type 2 diabetes and the cardio–renal–metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists

The impact of type 2 diabetes (T2D) extends beyond mere management of blood glucose; it also encompasses related cardiovascular, renal and metabolic issues. This interconnected framework, known as the cardio-renal-metabolic (CRM) syndrome, calls for a shift in therapeutic approach. While traditional treatments have mad...

Clipper F. Young, Namrita George, Alexander Olson et al. · 0 citations
Review Open access Nov 2026

Cardiometabolic benefits of glucagon-like peptide-1 receptor agonists and dual agonists: from obesity and diabetes to heart failure with preserved ejection fraction.

INTRODUCTION Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalisations and is increasing in prevalence, largely driven by obesity and Type 2 Diabetes Mellitus (T2DM). Glucagon-like-peptide receptor agonists (GLP-1 RAs) and the dual GLP-1/GIP agonist, tirzepatide...

R. Chotalia, Owais Ghias, Muhammad Usman Shah et al. · 0 citations
Review Open access Sep 2026

BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from glucose-lowering agents for type 2 diabetes (T2D) into multifunctional therapies with effects extending across multiple metabolic and organ systems. This review summarizes current evidence regarding the pleiotropic effects, safety profile, and futur...

M. Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al. · 0 citations
Review Open access Sep 2026

Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review

Obesity is a rapidly increasing global health challenge that is strongly linked to the cardiorenometabolic syndrome, cardiovascular morbidity, and mortality. Lifestyle interventions remain the cornerstone of treatment, but average long-term weight loss is modest and durable weight maintenance is often limited. Bariatri...

Susan J. F. van Maren, Eveline P. M. van Doorn, Mark M. Smits et al. · 1 citation
Sep 2026

Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists

Obesity is now a major global public health concern and a recognised risk factor for Cardiovascular Disease (CVD), the leading cause of morbidity and mortality worldwide. Chronic lowgrade inflammation, oxidative stress, insulin resistance, dyslipidemia, and endothelial dysfunction are promoted by excessive adiposit...

Amandeep Kaur, Okesh Saini, M. Haneef et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.